Sebanyak 184 item atau buku ditemukan

Anemia

Prevalence, Risk Factors and Management Strategies

Anaemia is defined as the decrease in haemoglobin from normal values either by loss of red blood cells or deficit in production or both. Haemoglobin is the major transporter of oxygen. The variation in haemoglobin is therefore a factor in determining the cardiac output. This book begins by discussing the effects anaemia has on heart diseases. The book then continues to discuss the influence of iron deficiency anaemia and recovery on oxidative/antioxidant status; influence of iron deficiency anaemia on bone metabolism; sickle cell anaemia; anaemia in myelodysplastic syndromes; transfusion in chronic anaemia; the prevalence, risk factors and management with a focus on chronic kidney disease; strategy for treating anaemia in chronic kidney disease patients from the standpoint of iron utility; and parasitic anaemia.

Haemoglobin is the major transporter of oxygen. The variation in haemoglobin is therefore a factor in determining the cardiac output. This book begins by discussing the effects anaemia has on heart diseases.

Sickle Cell Anemia

From Basic Science to Clinical Practice

Although sickle cell anemia was the first molecular disease to be identified, its complex and fascinating pathophysiology is still not fully understood. A single mutation in the beta-globin gene incurs numerous molecular and cellular mechanisms that contribute to the plethora of symptoms associated with the disease. Our knowledge regarding sickle cell disease mechanisms, while still not complete, has broadened considerably over the last decades. Sickle Cell Anemia: From Basic Science to Clinical Practice aims to provide an update on our current understanding of the disease’s pathophysiology and use this information as a basis to discuss its manifestations in childhood and adulthood. Current therapies and prospects for the development of new approaches for the management of the disease are also covered.

Although sickle cell anemia was the first molecular disease to be identified, its complex and fascinating pathophysiology is still not fully understood.

Anemia in the Elderly

Anemia in the elderly, known as the silent epidemic, afflicts 3 million people in the U.S. ages 65 or older. This reference, complete with the most recent findings, answers all the crucial questions regarding anemia in the elderly.

When should the suspicion for Myelodysplastic Syndrome be ruled out and what are the clues? This book addresses these and many other important questions with a review of the most recent findings.

Aplastic Anemia

Pathophysiology and Treatment

Comprehensive and up-to-date clinical reference, with an emphasis on treatment.

Comprehensive and up-to-date clinical reference, with an emphasis on treatment.

Aplastic Anemia: New Insights for the Healthcare Professional: 2013 Edition

ScholarlyBrief

Aplastic Anemia: New Insights for the Healthcare Professional: 2013 Edition is a ScholarlyBrief™ that delivers timely, authoritative, comprehensive, and specialized information about Genetics in a concise format. The editors have built Aplastic Anemia: New Insights for the Healthcare Professional: 2013 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Genetics in this book to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Aplastic Anemia: New Insights for the Healthcare Professional: 2013 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

The editors have built Aplastic Anemia: New Insights for the Healthcare Professional: 2013 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Genetics in this book to be deeper than what you ...

Aplastic Anemia and Other Bone Marrow Failure Syndromes

During the past decade, there have been numerous direct and indirect scientific contributions to both the etiology and therapy of aplastic anemia and related bone marrow failure syndromes. Clinical observations, such as autologous bone marrow recovery after conditioning with immunosup pressive agents for bone marrow transplantation; failure to achieve en graftment in some identical twins without prior immunosuppressive ther apy; and hematologic response to immunosuppressive agents, have led to the concept of immune-mediated etiology of acquired aplastic anemia. Such a concept was further strengthened by laboratory findings, implicat ing the role of activated cytotoxic T lymphocytes and abnormal produc tion of inhibitory lymphokines. The immunologic mechanisms may also apply to the idiosyncratic bone marrow aplasias associated with drugs, toxic chemicals, and viruses. These agents may alter normal cellular recog nition sites by interacting with cellular components and result in loss of self tolerance. Immunologic mechanisms have long been advocated in many other organ failures, and the hemopoietic organ is no exception. It is of interest that parallel clinical and laboratory investigations in juvenile diabetes mellitus type I and in rodent models of this disease have yielded results compatible with the same pathogenic mechanisms. The infiltration of pancreatic islets by activated T lymphocytes, functional and morphological alterations of islet cells upon incubation with lymphokines such as gamma interferon and tumor necrosis factor, and clinical response to cyclosporine are a few examples.

During the past decade, there have been numerous direct and indirect scientific contributions to both the etiology and therapy of aplastic anemia and related bone marrow failure syndromes.

Renal Anemia

Is the nephrology community facilitating excess cardiovascular deaths in patients with kidney failure and anemia by treating to a subnormal hematocrit? Why have clinicians and nephrologists permitted health insurance companies and the government to decide when anemia therapy should begin in persons with progressive kidney failure? Is iron the only variable that can be manipulated to maximize response to recombinant erythropoietin? Are we using too much intravenous iron in kidney failure patients, and is oral iron supplementation worthless in sustaining iron stores during long-term erythropoietin treatment? When does left ventricular hypertrophy begin to emerge in patients with progressive renal disease and is there convincing evidence that anemia is a significant cause of LVH in this setting? Is darbepoetin alfa, a new novel, long-acting erythropoietin, really superior to recombinant erythropoietin? This book is a compilation of proceedings from a conference in Brooklyn convened to address these and other controversial and unresolved issues in renal anemia management.

This book is a compilation of proceedings from a conference in Brooklyn convened to address these and other controversial and unresolved issues in renal anemia management.

Aplastic Anemia

Pathophysiology and Approaches to Therapy

Research on aplastic anaemia has until recently been limited to clinical description, morphology and epidemiology. New methods to culture haemopoietic cells, and advances in our knowledge of proliferation and differentiation in the haemopoietic cell system .opened a new area of scientific interest for this "prototype" of haemopoietic failure. In addition, bone marrow transplantation became not only a clinical method of treatment, but also a source of data useful for the discussion of pathophysiological models of aplastic anaemia. This situation prompted us to arrange an international con ference on aplastic anaemia, with particular emphasis on its patho physiology and the rationals of the current therapeutic approaches. This conference was held at Schloss Reisensburg from July 20-22, 1978 with the participation of both experimental and clinical scientists active in this field or in related areas of research. The proceedings of the symposion reflect the present knowledge as well as the many new questions which arose from the discussions. The editors are gratefully indebted to the participants of this meeting, to Gerlinde Trogele and all the co-workers of the Uni versity of Ulm engaged in preparation of this symposium and of this volume, and last not least to all sponsors who provided the financial basis for this scientific event.

The editors are gratefully indebted to the participants of this meeting, to Gerlinde Trogele and all the co-workers of the Uni versity of Ulm engaged in preparation of this symposium and of this volume, and last not least to all sponsors ...

Your Guide to Anemia

This book by the National Institutes of Health (Publication 11-7629) and the National Heart, Lung, and Blood Institute provides an overview of anemia. You've probably picked up this book because you've read about anemia and are curious to learn more. Perhaps you've just been diagnosed, or a family member has been. Or, you've had anemia for a while, and you want to learn more about it. People of all ages, races, and ethnicities can develop anemia at some point in their lives. There are many types of anemia, and they are linked to a variety of diseases and conditions. Some types of anemia are very common, and some are very rare. Some are very mild and have little or no impact on a person's life. Some are severe and can even be life-threatening if not treated aggressively. All anemias have one thing in common, though: They all affect your blood, and that affects your overall health. The good news is that anemia often can be successfully treated or even prevented. It starts with general information—what causes anemia, who is at risk, how it's diagnosed, and how it's treated. Then, the book goes into more detail about major types of anemia: iron-deficiency, pernicious, aplastic, and hemolytic. The book wraps up with some closing thoughts about leading a healthy lifestyle, working with your doctor, and talking with your family. These are important things to think about when it comes to anemia. The book doesn't provide detailed information about all types of anemia.

These are important things to think about when it comes to anemia. The book doesn't provide detailed information about all types of anemia.

Case Studies in Immunology: Autoimmune Hemolytic Anemia

A Clinical Companion

This case study is about an autoimmune disease triggered by infection. It describes how Gwendolen Fairfax, a healthy, unmarried 34-year-old bank manager, who developed the sudden onset of fever, cough and anemia, was started on erythromycin by intravenous administration for treatment.

This case study is about an autoimmune disease triggered by infection.